Features

The metaverse is expected to have far-reaching applications in sectors such as healthcare, manufacturing, education/job training, and communications. What is the metaverse exactly, and what technologies and functions are in play?

Oncology continues to be the leading therapeutic sector in the global bio/pharma market on a value basis and in growth rates. What do the numbers show, and what other therapeutic sectors rank high in growth prospects?

Facing limited industry capacity, both large and small CDMOs continue to expand capacity for cell and gene therapies, but will demand for outsourced services by bio/pharma companies stay strong in the near term? 

Inflationary pressures, in the form of higher energy, raw materials, and shipping costs, have tightened margins across all industries, including the bio/pharma industry. When will relief be on the way? 

Euroapi, a CDMO of small-molecule APIs spun off from Sanofi, has launched as a stand-alone publicly traded company. The CDMO projects 2022 revenues of $1 billion. What’s behind the new company?

The fortunes of the generics/biosimilars market will rest on one of the largest patent cliffs upcoming over the next five years. What do the numbers show, and what key trends are in the mix?

After reaching growth of 12% in 2021, in large measure due to COVID-19 products, growth in the US bio/pharma market is projected to moderate to pre-pandemic levels. What are the near-term outlook and key trends?

What countries lead in API manufacturing facilities for generic drugs? The location of manufacturing facilities is an important consideration as policymakers evaluate ways to mitigate supply-chain vulnerabilities.

At the request of Congress, the National Academies of Sciences, Engineering, and Medicine issued recommendations to improve the resiliency of the US pharma supply chain, including public disclosure of sourcing and manufacturing information. 

Increasing the use of digital technologies, such as artificial intelligence, blockchain, and predictive analytics in supply-chain operations is a priority for many executives. Senior executives weigh in on the opportunities and challenges.